No connection

Search Results

GOSS vs SERA

GOSS
Gossamer Bio, Inc.
BEARISH
Price
$0.37
Market Cap
$87.2M
Sector
Healthcare
AI Confidence
95%
SERA
Sera Prognostics, Inc.
BEARISH
Price
$2.30
Market Cap
$90.0M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
GOSS
--
SERA
--
Forward P/E
GOSS
-2.23
SERA
-3.36
P/B Ratio
GOSS
-0.71
SERA
1.19
P/S Ratio
GOSS
1.8
SERA
1111.49
EV/EBITDA
GOSS
-0.94
SERA
-1.49

Profitability

Gross Margin
GOSS
100.0%
SERA
-102.47%
Operating Margin
GOSS
-333.65%
SERA
-89540.0%
Profit Margin
GOSS
0.0%
SERA
0.0%
ROE
GOSS
--
SERA
-51.83%
ROA
GOSS
-41.86%
SERA
-26.15%

Growth

Revenue Growth
GOSS
47.1%
SERA
-58.3%
Earnings Growth
GOSS
--
SERA
--

Financial Health

Debt/Equity
GOSS
--
SERA
0.03
Current Ratio
GOSS
2.64
SERA
1.69
Quick Ratio
GOSS
2.36
SERA
1.62

Dividends

Dividend Yield
GOSS
--
SERA
--
Payout Ratio
GOSS
0.0%
SERA
0.0%

AI Verdict

GOSS BEARISH

GOSS exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating the weakest possible fundamental health. The company suffers from negative equity (Price/Book of -0.71) and an unsustainable operating margin of -333.65%. Despite positive revenue growth, the stock is in a catastrophic technical death spiral, losing over 85% of its value in the last six months. The massive discrepancy between the current price ($0.37) and the analyst target ($3.69) suggests a significant lag in analyst updates or extreme speculative optimism not supported by the deterministic data.

Strengths
Strong YoY revenue growth of 47.10%
Healthy short-term liquidity with a Current Ratio of 2.64
Quick Ratio of 2.36 suggests immediate obligations can be met
Risks
Negative Book Value (P/B -0.71) indicating liabilities exceed assets
Piotroski F-Score of 0/9 signals severe fundamental deterioration
Extreme price decay with a 5-year decline of 95.6%
SERA BEARISH

SERA presents a contradictory profile with a stable Piotroski F-Score of 6/9 but catastrophic operational metrics. While the balance sheet remains lean with very low debt (D/E 0.03) and adequate liquidity, the company is experiencing a severe revenue collapse (-58.3% YoY) and negative gross margins (-102.47%), indicating that the cost of producing its services exceeds the revenue generated. The extreme Price-to-Sales ratio (1111.49) and aggressive insider selling suggest a lack of confidence in the current business model, rendering the single analyst's 'strong buy' rating highly speculative.

Strengths
Low leverage with a Debt/Equity ratio of 0.03
Stable short-term liquidity (Current Ratio 1.69)
Piotroski F-Score of 6/9 indicates stable financial health relative to its own history
Risks
Severe revenue contraction (-58.3% YoY and Q/Q)
Negative gross margins (-102.47%) indicating a non-viable cost structure
Extreme valuation relative to sales (P/S 1111.49)

Compare Another Pair

GOSS vs SERA: Head-to-Head Comparison

This page compares Gossamer Bio, Inc. (GOSS) and Sera Prognostics, Inc. (SERA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile